Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thiazoles | 69 | 2024 | 1509 | 13.690 |
Why?
|
Atrial Fibrillation | 121 | 2024 | 5201 | 11.800 |
Why?
|
Warfarin | 78 | 2024 | 1516 | 11.310 |
Why?
|
Anticoagulants | 126 | 2024 | 4896 | 10.870 |
Why?
|
Pyridines | 71 | 2024 | 2877 | 10.200 |
Why?
|
Anticholesteremic Agents | 73 | 2024 | 988 | 9.790 |
Why?
|
Acute Coronary Syndrome | 95 | 2023 | 2362 | 9.550 |
Why?
|
Cholesterol, LDL | 75 | 2024 | 2422 | 5.880 |
Why?
|
Myocardial Infarction | 171 | 2024 | 11891 | 5.860 |
Why?
|
Stroke | 98 | 2024 | 9945 | 5.410 |
Why?
|
Hemorrhage | 77 | 2024 | 3604 | 5.370 |
Why?
|
Embolism | 23 | 2023 | 408 | 4.980 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 57 | 2023 | 3333 | 4.940 |
Why?
|
Thromboembolism | 17 | 2021 | 1016 | 4.060 |
Why?
|
Platelet Aggregation Inhibitors | 63 | 2022 | 3201 | 3.630 |
Why?
|
Thrombolytic Therapy | 64 | 2018 | 2108 | 3.550 |
Why?
|
Fibrinolytic Agents | 59 | 2022 | 2167 | 3.380 |
Why?
|
Hypolipidemic Agents | 16 | 2024 | 626 | 3.300 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 39 | 2017 | 638 | 3.130 |
Why?
|
Hypercholesterolemia | 18 | 2020 | 1155 | 2.960 |
Why?
|
Atherosclerosis | 28 | 2024 | 3524 | 2.880 |
Why?
|
Double-Blind Method | 97 | 2024 | 12412 | 2.580 |
Why?
|
Cardiovascular Diseases | 61 | 2024 | 15740 | 2.350 |
Why?
|
Antibodies, Monoclonal | 44 | 2023 | 9196 | 2.340 |
Why?
|
Angina, Unstable | 30 | 2022 | 926 | 2.320 |
Why?
|
Electrocardiography | 63 | 2018 | 6413 | 2.180 |
Why?
|
Administration, Oral | 42 | 2024 | 4044 | 2.160 |
Why?
|
Simvastatin | 19 | 2023 | 352 | 1.970 |
Why?
|
Blood Coagulation | 18 | 2024 | 1156 | 1.910 |
Why?
|
Angioplasty, Balloon, Coronary | 30 | 2016 | 1880 | 1.900 |
Why?
|
Thiophenes | 11 | 2014 | 587 | 1.680 |
Why?
|
Proprotein Convertases | 10 | 2015 | 97 | 1.650 |
Why?
|
Treatment Outcome | 173 | 2024 | 64947 | 1.640 |
Why?
|
Myocardial Revascularization | 17 | 2021 | 841 | 1.550 |
Why?
|
Dyslipidemias | 10 | 2020 | 895 | 1.500 |
Why?
|
Aged | 242 | 2024 | 168995 | 1.470 |
Why?
|
Coronary Angiography | 57 | 2020 | 4560 | 1.470 |
Why?
|
Drug Therapy, Combination | 54 | 2023 | 6499 | 1.450 |
Why?
|
Randomized Controlled Trials as Topic | 57 | 2024 | 10340 | 1.450 |
Why?
|
Risk Assessment | 64 | 2024 | 24086 | 1.360 |
Why?
|
Humans | 467 | 2024 | 760261 | 1.350 |
Why?
|
Vitamin K | 4 | 2020 | 321 | 1.250 |
Why?
|
Secondary Prevention | 12 | 2024 | 1548 | 1.250 |
Why?
|
Diabetes Mellitus | 15 | 2023 | 5884 | 1.240 |
Why?
|
Dose-Response Relationship, Drug | 41 | 2024 | 10829 | 1.190 |
Why?
|
Risk Factors | 128 | 2024 | 74269 | 1.170 |
Why?
|
Liver Diseases | 4 | 2019 | 1301 | 1.150 |
Why?
|
Practice Guidelines as Topic | 24 | 2020 | 7468 | 1.140 |
Why?
|
Middle Aged | 232 | 2024 | 220175 | 1.120 |
Why?
|
Intracranial Hemorrhages | 11 | 2023 | 844 | 1.110 |
Why?
|
Enoxaparin | 9 | 2012 | 397 | 1.110 |
Why?
|
Factor Xa | 8 | 2023 | 168 | 1.110 |
Why?
|
Peptides | 21 | 2017 | 4358 | 1.110 |
Why?
|
Male | 278 | 2024 | 359413 | 1.090 |
Why?
|
Clinical Trials, Phase III as Topic | 11 | 2023 | 859 | 1.070 |
Why?
|
Female | 281 | 2024 | 391011 | 1.050 |
Why?
|
Morpholines | 5 | 2014 | 583 | 1.000 |
Why?
|
Ticlopidine | 13 | 2014 | 895 | 0.980 |
Why?
|
Stents | 14 | 2014 | 3303 | 0.930 |
Why?
|
Azetidines | 7 | 2015 | 137 | 0.920 |
Why?
|
ATP Citrate (pro-S)-Lyase | 1 | 2023 | 22 | 0.900 |
Why?
|
Digoxin | 2 | 2017 | 247 | 0.880 |
Why?
|
Myocardial Reperfusion | 14 | 2014 | 347 | 0.860 |
Why?
|
Lipoprotein(a) | 9 | 2024 | 499 | 0.860 |
Why?
|
Heparin | 15 | 2015 | 1655 | 0.830 |
Why?
|
Anti-Arrhythmia Agents | 3 | 2017 | 784 | 0.830 |
Why?
|
Plastics | 1 | 2022 | 115 | 0.800 |
Why?
|
Niacin | 4 | 2019 | 119 | 0.800 |
Why?
|
Venous Thromboembolism | 8 | 2021 | 1866 | 0.790 |
Why?
|
Tissue Plasminogen Activator | 21 | 2009 | 1190 | 0.790 |
Why?
|
Time Factors | 62 | 2024 | 40133 | 0.770 |
Why?
|
Drug Administration Schedule | 20 | 2019 | 4900 | 0.750 |
Why?
|
Peripheral Arterial Disease | 4 | 2022 | 1305 | 0.750 |
Why?
|
Coronary Artery Disease | 13 | 2024 | 6661 | 0.750 |
Why?
|
Heart Failure | 25 | 2024 | 11835 | 0.730 |
Why?
|
Heart Valve Diseases | 3 | 2017 | 1047 | 0.720 |
Why?
|
Serine Proteinase Inhibitors | 5 | 2020 | 179 | 0.710 |
Why?
|
Nucleic Acids | 1 | 2022 | 188 | 0.670 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2018 | 1256 | 0.670 |
Why?
|
Patient Care Planning | 4 | 2017 | 909 | 0.660 |
Why?
|
Cholesterol, HDL | 9 | 2022 | 1817 | 0.650 |
Why?
|
Troponin T | 5 | 2024 | 774 | 0.640 |
Why?
|
Immunoglobulin Fab Fragments | 11 | 2011 | 465 | 0.620 |
Why?
|
Aged, 80 and over | 47 | 2024 | 58947 | 0.600 |
Why?
|
Follow-Up Studies | 50 | 2021 | 39254 | 0.600 |
Why?
|
Lipids | 5 | 2019 | 3336 | 0.580 |
Why?
|
Antithrombins | 8 | 2018 | 313 | 0.570 |
Why?
|
Cardiovascular Agents | 5 | 2013 | 864 | 0.570 |
Why?
|
Piperazines | 8 | 2016 | 2520 | 0.560 |
Why?
|
Gastrointestinal Hemorrhage | 4 | 2019 | 1130 | 0.550 |
Why?
|
Mitral Valve Stenosis | 1 | 2019 | 348 | 0.550 |
Why?
|
Europe | 12 | 2020 | 3433 | 0.550 |
Why?
|
American Heart Association | 10 | 2023 | 1081 | 0.550 |
Why?
|
Guideline Adherence | 6 | 2020 | 2283 | 0.540 |
Why?
|
Proportional Hazards Models | 21 | 2021 | 12532 | 0.530 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2018 | 379 | 0.530 |
Why?
|
Eicosapentaenoic Acid | 6 | 2022 | 613 | 0.520 |
Why?
|
Hospital Mortality | 14 | 2020 | 5420 | 0.520 |
Why?
|
Thrombosis | 8 | 2018 | 3052 | 0.520 |
Why?
|
Plasminogen Activators | 7 | 2009 | 199 | 0.510 |
Why?
|
Cardiology | 5 | 2020 | 1723 | 0.510 |
Why?
|
Morphine | 1 | 2020 | 656 | 0.510 |
Why?
|
Death, Sudden, Cardiac | 5 | 2022 | 1572 | 0.510 |
Why?
|
Fatty Acids | 1 | 2023 | 1805 | 0.510 |
Why?
|
Drug Monitoring | 7 | 2018 | 966 | 0.500 |
Why?
|
Aortic Valve Stenosis | 3 | 2024 | 2064 | 0.500 |
Why?
|
Coronary Disease | 12 | 2020 | 5993 | 0.500 |
Why?
|
Coronary Circulation | 17 | 2014 | 1578 | 0.490 |
Why?
|
Pyridones | 8 | 2019 | 788 | 0.480 |
Why?
|
Withholding Treatment | 2 | 2018 | 613 | 0.470 |
Why?
|
Clinical Trials as Topic | 25 | 2020 | 8058 | 0.470 |
Why?
|
Prosthesis Implantation | 1 | 2019 | 593 | 0.470 |
Why?
|
Heart Valve Prosthesis | 3 | 2018 | 1494 | 0.450 |
Why?
|
Device Removal | 1 | 2019 | 634 | 0.450 |
Why?
|
Thrombocytopenia | 4 | 2015 | 1174 | 0.450 |
Why?
|
Cognition | 5 | 2022 | 6948 | 0.450 |
Why?
|
Survival Rate | 27 | 2019 | 12806 | 0.440 |
Why?
|
Ventricular Fibrillation | 2 | 2013 | 539 | 0.440 |
Why?
|
Venous Thrombosis | 3 | 2020 | 1293 | 0.440 |
Why?
|
Adenosine | 1 | 2018 | 833 | 0.430 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2014 | 96 | 0.430 |
Why?
|
Pacemaker, Artificial | 1 | 2019 | 815 | 0.430 |
Why?
|
Benzimidazoles | 3 | 2014 | 858 | 0.420 |
Why?
|
Postoperative Complications | 6 | 2018 | 15680 | 0.420 |
Why?
|
Serine Endopeptidases | 9 | 2015 | 1021 | 0.410 |
Why?
|
Angioplasty | 2 | 2012 | 360 | 0.410 |
Why?
|
Lung Diseases, Interstitial | 1 | 2021 | 907 | 0.400 |
Why?
|
Incidence | 23 | 2021 | 21378 | 0.400 |
Why?
|
Heart Valve Prosthesis Implantation | 3 | 2018 | 1583 | 0.400 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2016 | 347 | 0.390 |
Why?
|
Heparin, Low-Molecular-Weight | 4 | 2016 | 346 | 0.390 |
Why?
|
Subtilisins | 3 | 2022 | 82 | 0.390 |
Why?
|
Risk Reduction Behavior | 4 | 2020 | 1109 | 0.380 |
Why?
|
Managed Care Programs | 1 | 2016 | 939 | 0.380 |
Why?
|
Hypertriglyceridemia | 3 | 2024 | 316 | 0.370 |
Why?
|
Troponin | 6 | 2022 | 516 | 0.370 |
Why?
|
Obesity | 6 | 2020 | 12915 | 0.370 |
Why?
|
Drugs, Investigational | 1 | 2013 | 214 | 0.370 |
Why?
|
Growth Differentiation Factor 15 | 4 | 2024 | 192 | 0.370 |
Why?
|
Comorbidity | 12 | 2020 | 10552 | 0.370 |
Why?
|
Prognosis | 43 | 2023 | 29636 | 0.360 |
Why?
|
International Normalized Ratio | 6 | 2020 | 387 | 0.360 |
Why?
|
Coronary Artery Bypass | 9 | 2021 | 2273 | 0.350 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 3 | 2020 | 253 | 0.350 |
Why?
|
Pain Threshold | 1 | 2014 | 600 | 0.350 |
Why?
|
Tyrosine | 6 | 2011 | 1440 | 0.350 |
Why?
|
Diabetes Mellitus, Type 2 | 10 | 2023 | 12281 | 0.350 |
Why?
|
Streptokinase | 2 | 2009 | 187 | 0.350 |
Why?
|
Creatine Kinase, MB Form | 7 | 2018 | 211 | 0.340 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2220 | 0.340 |
Why?
|
Kaplan-Meier Estimate | 9 | 2020 | 6545 | 0.340 |
Why?
|
Pyrazoles | 8 | 2019 | 1992 | 0.330 |
Why?
|
Defibrillators, Implantable | 1 | 2019 | 1499 | 0.330 |
Why?
|
Natriuretic Peptide, Brain | 7 | 2024 | 1705 | 0.320 |
Why?
|
Heart Function Tests | 1 | 2010 | 319 | 0.320 |
Why?
|
Lipoproteins, LDL | 3 | 2019 | 641 | 0.320 |
Why?
|
Severity of Illness Index | 18 | 2020 | 15827 | 0.310 |
Why?
|
Peptide Fragments | 8 | 2024 | 5120 | 0.300 |
Why?
|
United States | 35 | 2022 | 72363 | 0.300 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1925 | 0.300 |
Why?
|
Hyperglycemia | 3 | 2011 | 1380 | 0.290 |
Why?
|
Memory | 1 | 2017 | 2179 | 0.290 |
Why?
|
Skull Fractures | 1 | 2009 | 201 | 0.290 |
Why?
|
North America | 6 | 2019 | 1282 | 0.290 |
Why?
|
Clinical Protocols | 2 | 2011 | 1439 | 0.290 |
Why?
|
Half-Life | 2 | 2018 | 652 | 0.290 |
Why?
|
Tachycardia, Ventricular | 2 | 2013 | 1302 | 0.290 |
Why?
|
Aspirin | 13 | 2020 | 3365 | 0.290 |
Why?
|
C-Reactive Protein | 5 | 2024 | 3822 | 0.290 |
Why?
|
Chest Pain | 1 | 2014 | 1106 | 0.280 |
Why?
|
Recombinant Proteins | 10 | 2019 | 6543 | 0.280 |
Why?
|
Insulin Resistance | 3 | 2024 | 3960 | 0.280 |
Why?
|
Hypopituitarism | 1 | 2009 | 248 | 0.280 |
Why?
|
Fibrin | 1 | 2009 | 505 | 0.280 |
Why?
|
Stroke Volume | 9 | 2023 | 5513 | 0.270 |
Why?
|
Enzyme Inhibitors | 2 | 2015 | 3726 | 0.270 |
Why?
|
Helminth Proteins | 1 | 2007 | 172 | 0.270 |
Why?
|
Hospitalization | 11 | 2021 | 10761 | 0.270 |
Why?
|
Endpoint Determination | 3 | 2021 | 597 | 0.260 |
Why?
|
Troponin I | 4 | 2016 | 634 | 0.260 |
Why?
|
Triglycerides | 6 | 2024 | 2476 | 0.260 |
Why?
|
Atrial Function, Left | 2 | 2019 | 186 | 0.260 |
Why?
|
Medication Adherence | 3 | 2016 | 2163 | 0.260 |
Why?
|
Multivariate Analysis | 12 | 2017 | 12156 | 0.240 |
Why?
|
Clinical Trials, Phase II as Topic | 8 | 2018 | 629 | 0.240 |
Why?
|
Goals | 1 | 2010 | 708 | 0.240 |
Why?
|
Survival Analysis | 18 | 2019 | 10185 | 0.240 |
Why?
|
Chalcones | 1 | 2024 | 29 | 0.230 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 2544 | 0.230 |
Why?
|
Muscular Diseases | 2 | 2020 | 551 | 0.230 |
Why?
|
Cardiac Surgical Procedures | 3 | 2018 | 3618 | 0.230 |
Why?
|
Research Design | 6 | 2014 | 6181 | 0.230 |
Why?
|
Infusions, Intravenous | 7 | 2015 | 2235 | 0.230 |
Why?
|
beta-Alanine | 2 | 2014 | 82 | 0.230 |
Why?
|
Catheter Ablation | 1 | 2017 | 2755 | 0.220 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3762 | 0.220 |
Why?
|
Cholesterol | 4 | 2023 | 2925 | 0.220 |
Why?
|
Coronary Stenosis | 4 | 2013 | 820 | 0.220 |
Why?
|
Quality of Health Care | 4 | 2011 | 4361 | 0.220 |
Why?
|
Age Factors | 13 | 2022 | 18415 | 0.220 |
Why?
|
Coronary Vessels | 8 | 2015 | 3112 | 0.220 |
Why?
|
Combined Modality Therapy | 10 | 2016 | 8551 | 0.220 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2009 | 819 | 0.210 |
Why?
|
Cardiovascular System | 2 | 2021 | 850 | 0.210 |
Why?
|
Prospective Studies | 23 | 2023 | 54263 | 0.210 |
Why?
|
Apolipoprotein C-III | 1 | 2024 | 209 | 0.210 |
Why?
|
Body Weight | 3 | 2024 | 4613 | 0.200 |
Why?
|
Blood Glucose | 7 | 2024 | 6375 | 0.200 |
Why?
|
Surgical Procedures, Operative | 1 | 2014 | 1919 | 0.200 |
Why?
|
Liver | 2 | 2024 | 7512 | 0.200 |
Why?
|
Diagnostic Imaging | 2 | 2013 | 3526 | 0.200 |
Why?
|
Bioprosthesis | 2 | 2017 | 599 | 0.200 |
Why?
|
Creatinine | 8 | 2016 | 1906 | 0.200 |
Why?
|
Cause of Death | 8 | 2019 | 3723 | 0.200 |
Why?
|
Recurrence | 12 | 2018 | 8487 | 0.200 |
Why?
|
Lipogenesis | 1 | 2023 | 210 | 0.200 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2805 | 0.190 |
Why?
|
Receptors, LDL | 4 | 2018 | 491 | 0.190 |
Why?
|
Patient Selection | 6 | 2016 | 4276 | 0.190 |
Why?
|
Models, Theoretical | 1 | 2013 | 3561 | 0.190 |
Why?
|
Drug Interactions | 3 | 2015 | 1426 | 0.190 |
Why?
|
Drug-Eluting Stents | 3 | 2014 | 758 | 0.190 |
Why?
|
Environmental Pollution | 1 | 2022 | 123 | 0.190 |
Why?
|
Kidney | 6 | 2023 | 7072 | 0.190 |
Why?
|
Hyperlipidemias | 2 | 2018 | 782 | 0.190 |
Why?
|
Neoplasms | 3 | 2019 | 22066 | 0.190 |
Why?
|
Latin America | 2 | 2018 | 405 | 0.190 |
Why?
|
Retrospective Studies | 28 | 2023 | 80301 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.180 |
Why?
|
Sex Factors | 11 | 2022 | 10530 | 0.180 |
Why?
|
Oligopeptides | 3 | 2016 | 1188 | 0.180 |
Why?
|
Hypertension | 3 | 2019 | 8595 | 0.180 |
Why?
|
Adult | 43 | 2024 | 219847 | 0.180 |
Why?
|
Oligonucleotides | 1 | 2024 | 588 | 0.180 |
Why?
|
Cardiotonic Agents | 2 | 2016 | 546 | 0.180 |
Why?
|
Ultracentrifugation | 2 | 2018 | 183 | 0.180 |
Why?
|
Syndrome | 6 | 2006 | 3278 | 0.180 |
Why?
|
Subtilisin | 1 | 2020 | 12 | 0.180 |
Why?
|
Spectrum Analysis | 1 | 2022 | 453 | 0.180 |
Why?
|
Odds Ratio | 13 | 2017 | 9712 | 0.180 |
Why?
|
Glycine | 1 | 2003 | 663 | 0.170 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 239 | 0.170 |
Why?
|
Cost-Benefit Analysis | 5 | 2017 | 5507 | 0.170 |
Why?
|
Cholesterol, VLDL | 2 | 2018 | 71 | 0.170 |
Why?
|
Patient Admission | 3 | 2014 | 1384 | 0.170 |
Why?
|
Heart Conduction System | 3 | 2005 | 1016 | 0.160 |
Why?
|
Geography | 1 | 2001 | 661 | 0.160 |
Why?
|
Perioperative Care | 3 | 2018 | 1032 | 0.160 |
Why?
|
Registries | 7 | 2020 | 8449 | 0.160 |
Why?
|
Proteomics | 2 | 2023 | 3810 | 0.160 |
Why?
|
Evidence-Based Medicine | 6 | 2018 | 3696 | 0.160 |
Why?
|
Frail Elderly | 1 | 2024 | 747 | 0.160 |
Why?
|
Lasers | 1 | 2022 | 952 | 0.150 |
Why?
|
Apolipoproteins B | 4 | 2024 | 388 | 0.150 |
Why?
|
Forecasting | 3 | 2017 | 2931 | 0.150 |
Why?
|
Canada | 3 | 2017 | 2128 | 0.150 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2019 | 122 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
Emergency Medical Services | 3 | 2010 | 1927 | 0.150 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 488 | 0.140 |
Why?
|
Chi-Square Distribution | 7 | 2014 | 3466 | 0.140 |
Why?
|
Logistic Models | 11 | 2019 | 13311 | 0.140 |
Why?
|
Mortality | 3 | 2018 | 2916 | 0.140 |
Why?
|
Creatine Kinase | 5 | 2009 | 691 | 0.140 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 59 | 0.140 |
Why?
|
Sex Distribution | 4 | 2017 | 2295 | 0.140 |
Why?
|
Thrombophilia | 2 | 2016 | 307 | 0.140 |
Why?
|
Thiazolidinediones | 2 | 2010 | 465 | 0.140 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2016 | 60 | 0.140 |
Why?
|
Hirudins | 2 | 2016 | 194 | 0.140 |
Why?
|
Digitalis Glycosides | 1 | 2016 | 47 | 0.140 |
Why?
|
Echocardiography | 3 | 2019 | 4980 | 0.140 |
Why?
|
Genotype | 6 | 2022 | 12959 | 0.140 |
Why?
|
Electric Countershock | 2 | 2016 | 537 | 0.130 |
Why?
|
Ischemia | 2 | 2022 | 1893 | 0.130 |
Why?
|
Environmental Monitoring | 1 | 2022 | 1441 | 0.130 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2016 | 43 | 0.130 |
Why?
|
Rhabdomyolysis | 1 | 2017 | 155 | 0.130 |
Why?
|
Predictive Value of Tests | 18 | 2018 | 15273 | 0.130 |
Why?
|
Heart Atria | 2 | 2019 | 1344 | 0.130 |
Why?
|
Brain Ischemia | 2 | 2021 | 3127 | 0.130 |
Why?
|
Heptanoic Acids | 2 | 2008 | 347 | 0.130 |
Why?
|
Pravastatin | 2 | 2008 | 393 | 0.130 |
Why?
|
Internationality | 2 | 2018 | 1005 | 0.130 |
Why?
|
Vitamins | 1 | 2024 | 1635 | 0.130 |
Why?
|
Self-Assessment | 1 | 2017 | 393 | 0.120 |
Why?
|
Lymphocytes | 1 | 2023 | 2612 | 0.120 |
Why?
|
Kidney Function Tests | 3 | 2016 | 680 | 0.120 |
Why?
|
Psychological Tests | 1 | 2017 | 639 | 0.120 |
Why?
|
Risk | 9 | 2019 | 9629 | 0.120 |
Why?
|
Statistics as Topic | 3 | 2018 | 2363 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2015 | 1521 | 0.120 |
Why?
|
Cohort Studies | 13 | 2024 | 41317 | 0.120 |
Why?
|
Drug Dosage Calculations | 2 | 2011 | 118 | 0.120 |
Why?
|
Biological Assay | 2 | 2015 | 630 | 0.110 |
Why?
|
Atrioventricular Block | 1 | 2015 | 121 | 0.110 |
Why?
|
Atrial Flutter | 1 | 2016 | 258 | 0.110 |
Why?
|
Safety | 1 | 2018 | 1149 | 0.110 |
Why?
|
Heart Rate | 4 | 2016 | 4169 | 0.110 |
Why?
|
Platelet Aggregation | 4 | 2021 | 805 | 0.110 |
Why?
|
Government Regulation | 1 | 2018 | 526 | 0.110 |
Why?
|
Shock, Cardiogenic | 2 | 2010 | 734 | 0.110 |
Why?
|
Hemostatics | 1 | 2016 | 243 | 0.110 |
Why?
|
Amiodarone | 1 | 2015 | 218 | 0.110 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2019 | 2296 | 0.110 |
Why?
|
No-Reflow Phenomenon | 1 | 2013 | 17 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2061 | 0.110 |
Why?
|
Obesity, Abdominal | 1 | 2016 | 375 | 0.110 |
Why?
|
Multicenter Studies as Topic | 5 | 2020 | 1723 | 0.110 |
Why?
|
Hypoglycemic Agents | 3 | 2010 | 3149 | 0.110 |
Why?
|
Acute Disease | 5 | 2007 | 7268 | 0.110 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2017 | 450 | 0.110 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 2018 | 186 | 0.110 |
Why?
|
Statistics, Nonparametric | 4 | 2014 | 2852 | 0.110 |
Why?
|
Age Distribution | 3 | 2017 | 2893 | 0.110 |
Why?
|
Vascular Patency | 5 | 2010 | 901 | 0.110 |
Why?
|
Ventricular Function, Left | 3 | 2019 | 3870 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 2 | 2018 | 1799 | 0.100 |
Why?
|
Apolipoprotein B-100 | 1 | 2013 | 155 | 0.100 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2013 | 113 | 0.100 |
Why?
|
Heart Diseases | 2 | 2012 | 2809 | 0.100 |
Why?
|
Kidney Diseases | 5 | 2012 | 2093 | 0.100 |
Why?
|
Antithrombin Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
Myocardial Ischemia | 5 | 2011 | 2161 | 0.100 |
Why?
|
Blood Flow Velocity | 4 | 2005 | 1375 | 0.100 |
Why?
|
Databases, Factual | 4 | 2020 | 8018 | 0.100 |
Why?
|
Weather | 1 | 2013 | 227 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 296 | 0.100 |
Why?
|
Prosthesis Design | 2 | 2018 | 2127 | 0.100 |
Why?
|
Circadian Rhythm | 2 | 2013 | 2567 | 0.100 |
Why?
|
Injections, Intravenous | 3 | 2003 | 1388 | 0.100 |
Why?
|
Intra-Abdominal Fat | 1 | 2016 | 607 | 0.100 |
Why?
|
Body Mass Index | 5 | 2024 | 12901 | 0.090 |
Why?
|
Adenosine Monophosphate | 1 | 2013 | 283 | 0.090 |
Why?
|
Bundle-Branch Block | 1 | 2013 | 281 | 0.090 |
Why?
|
Economics, Pharmaceutical | 1 | 2011 | 88 | 0.090 |
Why?
|
Pyrroles | 2 | 2008 | 1137 | 0.090 |
Why?
|
Emergency Service, Hospital | 1 | 2010 | 7809 | 0.090 |
Why?
|
Lactones | 1 | 2013 | 319 | 0.090 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 853 | 0.090 |
Why?
|
Hospital Costs | 1 | 2017 | 976 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 951 | 0.090 |
Why?
|
Placebo Effect | 3 | 2019 | 511 | 0.090 |
Why?
|
Fasting | 1 | 2017 | 1603 | 0.090 |
Why?
|
Neutrophils | 1 | 2023 | 3770 | 0.090 |
Why?
|
Drug Costs | 2 | 2019 | 1184 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2018 | 1180 | 0.090 |
Why?
|
Quality Assurance, Health Care | 2 | 2012 | 2178 | 0.090 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2010 | 169 | 0.090 |
Why?
|
Reminder Systems | 1 | 2013 | 387 | 0.090 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1387 | 0.090 |
Why?
|
Primary Prevention | 1 | 2017 | 1207 | 0.080 |
Why?
|
Pilot Projects | 2 | 2017 | 8553 | 0.080 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14482 | 0.080 |
Why?
|
Amphetamine-Related Disorders | 1 | 2010 | 77 | 0.080 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2013 | 479 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2013 | 755 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2019 | 2627 | 0.080 |
Why?
|
Weight Gain | 1 | 2019 | 2347 | 0.080 |
Why?
|
Vascular Surgical Procedures | 1 | 1998 | 1469 | 0.080 |
Why?
|
Dementia | 1 | 2023 | 2638 | 0.080 |
Why?
|
Biological Transport | 1 | 2013 | 2087 | 0.080 |
Why?
|
Accidental Falls | 1 | 2016 | 1054 | 0.080 |
Why?
|
Cardiac Imaging Techniques | 1 | 2010 | 269 | 0.080 |
Why?
|
Antioxidants | 1 | 2016 | 1668 | 0.080 |
Why?
|
Angina Pectoris | 2 | 2009 | 969 | 0.080 |
Why?
|
Overweight | 1 | 2019 | 2421 | 0.070 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 1166 | 0.070 |
Why?
|
Takayasu Arteritis | 1 | 2009 | 95 | 0.070 |
Why?
|
Glucose Metabolism Disorders | 1 | 2007 | 52 | 0.070 |
Why?
|
Renal Insufficiency | 2 | 2011 | 820 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 12968 | 0.070 |
Why?
|
Inflammation | 2 | 2018 | 10757 | 0.070 |
Why?
|
Myocardial Contraction | 2 | 2011 | 1516 | 0.070 |
Why?
|
Patient Transfer | 1 | 2014 | 778 | 0.070 |
Why?
|
Protein Transport | 1 | 2013 | 1966 | 0.070 |
Why?
|
Analysis of Variance | 3 | 2012 | 6242 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1675 | 0.070 |
Why?
|
Fibrinolysis | 2 | 2010 | 332 | 0.070 |
Why?
|
Prediabetic State | 1 | 2013 | 550 | 0.070 |
Why?
|
Thrombin | 1 | 2009 | 593 | 0.070 |
Why?
|
Seasons | 1 | 2013 | 1523 | 0.070 |
Why?
|
Glomerular Filtration Rate | 3 | 2016 | 2178 | 0.070 |
Why?
|
Heart Rupture, Post-Infarction | 2 | 2003 | 48 | 0.070 |
Why?
|
Physicians, Family | 1 | 2009 | 349 | 0.070 |
Why?
|
New Zealand | 2 | 2019 | 355 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1802 | 0.070 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2009 | 389 | 0.070 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2013 | 1025 | 0.070 |
Why?
|
Cocaine-Related Disorders | 1 | 2010 | 460 | 0.070 |
Why?
|
Myoglobin | 3 | 2001 | 159 | 0.070 |
Why?
|
Acetanilides | 1 | 2007 | 169 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1395 | 0.070 |
Why?
|
Disease-Free Survival | 3 | 2008 | 6830 | 0.070 |
Why?
|
Injections, Subcutaneous | 2 | 2019 | 679 | 0.070 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 3800 | 0.070 |
Why?
|
Prevalence | 4 | 2017 | 15687 | 0.060 |
Why?
|
Quality of Life | 3 | 2018 | 13300 | 0.060 |
Why?
|
Patients | 2 | 2023 | 906 | 0.060 |
Why?
|
Chlamydophila Infections | 1 | 2005 | 22 | 0.060 |
Why?
|
Pulsatile Flow | 2 | 2004 | 320 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2021 | 22041 | 0.060 |
Why?
|
Heart Arrest | 1 | 2015 | 1506 | 0.060 |
Why?
|
Carrier Proteins | 2 | 2013 | 4938 | 0.060 |
Why?
|
Edema | 1 | 2009 | 772 | 0.060 |
Why?
|
Treatment Failure | 2 | 2009 | 2646 | 0.060 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 877 | 0.060 |
Why?
|
Postoperative Hemorrhage | 1 | 2008 | 422 | 0.060 |
Why?
|
Arterial Occlusive Diseases | 1 | 2009 | 752 | 0.060 |
Why?
|
Hospitals | 2 | 2012 | 3929 | 0.060 |
Why?
|
Asia | 2 | 2019 | 618 | 0.060 |
Why?
|
Endothelium, Vascular | 1 | 2016 | 4437 | 0.060 |
Why?
|
Animals | 8 | 2018 | 167940 | 0.060 |
Why?
|
Peroxisome Proliferator-Activated Receptors | 1 | 2024 | 61 | 0.060 |
Why?
|
Health Status | 1 | 2017 | 4081 | 0.060 |
Why?
|
Anemia | 2 | 2011 | 1511 | 0.060 |
Why?
|
Disease Management | 3 | 2021 | 2508 | 0.060 |
Why?
|
Life Style | 2 | 2015 | 3888 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2016 | 3811 | 0.060 |
Why?
|
Cardiac Output, Low | 1 | 2004 | 192 | 0.060 |
Why?
|
Radiography | 3 | 2010 | 6965 | 0.060 |
Why?
|
Propionates | 1 | 2024 | 182 | 0.060 |
Why?
|
Pharmacogenetics | 2 | 2020 | 680 | 0.060 |
Why?
|
Smoking | 3 | 2013 | 9070 | 0.060 |
Why?
|
Australia | 2 | 2019 | 1288 | 0.060 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 1935 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2311 | 0.050 |
Why?
|
Iceland | 1 | 2023 | 184 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2005 | 309 | 0.050 |
Why?
|
Models, Statistical | 4 | 2012 | 5073 | 0.050 |
Why?
|
Benzylamines | 1 | 2003 | 248 | 0.050 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2007 | 840 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17766 | 0.050 |
Why?
|
Mathematics | 1 | 2003 | 708 | 0.050 |
Why?
|
Up-Regulation | 3 | 2018 | 4127 | 0.050 |
Why?
|
Disease Progression | 3 | 2019 | 13505 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8621 | 0.050 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 1067 | 0.050 |
Why?
|
Europe, Eastern | 1 | 2001 | 72 | 0.050 |
Why?
|
Lipid Regulating Agents | 1 | 2021 | 28 | 0.050 |
Why?
|
Morbidity | 2 | 2020 | 1765 | 0.050 |
Why?
|
Fatigue | 1 | 2009 | 1544 | 0.050 |
Why?
|
Blood Platelets | 3 | 2021 | 2522 | 0.050 |
Why?
|
Platelet Count | 2 | 2004 | 777 | 0.050 |
Why?
|
Placebos | 2 | 2019 | 1672 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2001 | 141 | 0.050 |
Why?
|
Lipid Metabolism | 2 | 2024 | 1902 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2024 | 459 | 0.050 |
Why?
|
Ultrasonography, Interventional | 1 | 2009 | 1503 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12602 | 0.050 |
Why?
|
Myocardium | 4 | 2016 | 4688 | 0.050 |
Why?
|
Inpatients | 1 | 2012 | 2578 | 0.050 |
Why?
|
Myelin P2 Protein | 1 | 2000 | 20 | 0.050 |
Why?
|
Dyspnea | 1 | 2009 | 1352 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 429 | 0.050 |
Why?
|
ROC Curve | 2 | 2019 | 3568 | 0.050 |
Why?
|
Societies, Medical | 2 | 2010 | 3903 | 0.050 |
Why?
|
Pericardium | 2 | 2002 | 675 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4546 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2022 | 8551 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 2 | 2017 | 1724 | 0.040 |
Why?
|
Down-Regulation | 2 | 2018 | 2918 | 0.040 |
Why?
|
Probability | 2 | 2010 | 2476 | 0.040 |
Why?
|
Blood Pressure | 3 | 2024 | 8523 | 0.040 |
Why?
|
Thromboxane B2 | 1 | 2019 | 147 | 0.040 |
Why?
|
Single-Blind Method | 3 | 2016 | 1577 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 25928 | 0.040 |
Why?
|
Calcinosis | 2 | 2005 | 1478 | 0.040 |
Why?
|
Hemoglobins | 1 | 2005 | 1521 | 0.040 |
Why?
|
Critical Pathways | 1 | 2022 | 475 | 0.040 |
Why?
|
Pipecolic Acids | 1 | 1999 | 78 | 0.040 |
Why?
|
Leukocytosis | 1 | 2000 | 251 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3421 | 0.040 |
Why?
|
South America | 1 | 2019 | 181 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2003 | 1375 | 0.040 |
Why?
|
Reference Values | 3 | 2000 | 4920 | 0.040 |
Why?
|
Computer Security | 1 | 2020 | 260 | 0.040 |
Why?
|
Antidotes | 1 | 2019 | 138 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2020 | 303 | 0.040 |
Why?
|
Patient Care | 1 | 2004 | 624 | 0.040 |
Why?
|
Computer Simulation | 1 | 2012 | 6210 | 0.040 |
Why?
|
Italy | 2 | 2011 | 840 | 0.040 |
Why?
|
Adiponectin | 1 | 2024 | 1115 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 132 | 0.040 |
Why?
|
Point-of-Care Systems | 3 | 2001 | 1208 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2019 | 145 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2282 | 0.040 |
Why?
|
Length of Stay | 1 | 2012 | 6472 | 0.040 |
Why?
|
Thallium Radioisotopes | 1 | 1998 | 138 | 0.040 |
Why?
|
Hypoglycemia | 1 | 2005 | 888 | 0.040 |
Why?
|
Likelihood Functions | 2 | 1998 | 988 | 0.040 |
Why?
|
Fatty Liver | 1 | 2024 | 777 | 0.040 |
Why?
|
Primary Health Care | 1 | 2014 | 4649 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2022 | 708 | 0.040 |
Why?
|
Adolescent | 6 | 2012 | 87747 | 0.040 |
Why?
|
Microcirculation | 1 | 2022 | 1279 | 0.040 |
Why?
|
Lipoproteins | 1 | 2022 | 882 | 0.040 |
Why?
|
Acetates | 2 | 2011 | 322 | 0.040 |
Why?
|
Triage | 2 | 2001 | 982 | 0.030 |
Why?
|
Germany | 1 | 2019 | 875 | 0.030 |
Why?
|
Brazil | 1 | 2020 | 1214 | 0.030 |
Why?
|
Arginine | 2 | 2016 | 934 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 369 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2016 | 361 | 0.030 |
Why?
|
Insulin | 1 | 2010 | 6592 | 0.030 |
Why?
|
Young Adult | 3 | 2012 | 58673 | 0.030 |
Why?
|
Taiwan | 1 | 2017 | 503 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2017 | 297 | 0.030 |
Why?
|
Factor VIIa | 1 | 2016 | 103 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 5960 | 0.030 |
Why?
|
Telemedicine | 1 | 2013 | 3005 | 0.030 |
Why?
|
Models, Biological | 1 | 2012 | 9468 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11341 | 0.030 |
Why?
|
Data Collection | 2 | 2001 | 3317 | 0.030 |
Why?
|
Regional Blood Flow | 3 | 2004 | 1490 | 0.030 |
Why?
|
Calibration | 1 | 1998 | 816 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2016 | 389 | 0.030 |
Why?
|
Limb Salvage | 1 | 2017 | 466 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5783 | 0.030 |
Why?
|
Holidays | 1 | 2014 | 41 | 0.030 |
Why?
|
Norway | 1 | 2015 | 497 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2006 | 1945 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2003 | 1870 | 0.030 |
Why?
|
Markov Chains | 1 | 2017 | 971 | 0.030 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 366 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13249 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1998 | 1975 | 0.030 |
Why?
|
Isoenzymes | 3 | 2004 | 1690 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5324 | 0.030 |
Why?
|
Diet | 1 | 2011 | 8008 | 0.030 |
Why?
|
Drug Combinations | 2 | 2010 | 2024 | 0.030 |
Why?
|
Plasma | 1 | 2016 | 584 | 0.030 |
Why?
|
Cerebral Revascularization | 1 | 2015 | 249 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 1 | 2013 | 221 | 0.030 |
Why?
|
Limit of Detection | 1 | 2013 | 280 | 0.030 |
Why?
|
Drug Utilization | 1 | 2019 | 1195 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 1755 | 0.030 |
Why?
|
Chile | 1 | 2013 | 254 | 0.030 |
Why?
|
Information Dissemination | 1 | 2020 | 1132 | 0.030 |
Why?
|
Random Allocation | 1 | 2016 | 2394 | 0.030 |
Why?
|
Radial Artery | 1 | 2013 | 196 | 0.020 |
Why?
|
Hospitals, University | 1 | 2013 | 568 | 0.020 |
Why?
|
Pierre Robin Syndrome | 1 | 2013 | 117 | 0.020 |
Why?
|
Health Services Accessibility | 2 | 2014 | 5396 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2016 | 968 | 0.020 |
Why?
|
Genetic Variation | 2 | 2016 | 6540 | 0.020 |
Why?
|
Coronary Thrombosis | 1 | 2014 | 486 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2014 | 601 | 0.020 |
Why?
|
Africa | 1 | 2012 | 707 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2753 | 0.020 |
Why?
|
Kidney Failure, Chronic | 2 | 2016 | 2469 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2000 | 2804 | 0.020 |
Why?
|
Exercise Test | 2 | 2009 | 2125 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2000 | 2255 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 1933 | 0.020 |
Why?
|
Standard of Care | 1 | 2013 | 552 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1241 | 0.020 |
Why?
|
Bayes Theorem | 1 | 1998 | 2325 | 0.020 |
Why?
|
Regression Analysis | 3 | 2005 | 6361 | 0.020 |
Why?
|
Cerebral Hemorrhage | 2 | 2017 | 2660 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2011 | 711 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2022 | 7016 | 0.020 |
Why?
|
Patient Discharge | 1 | 2002 | 3475 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36247 | 0.020 |
Why?
|
Drug Approval | 1 | 2015 | 816 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2012 | 495 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 3613 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 2013 | 566 | 0.020 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20048 | 0.020 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2007 | 42 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2010 | 413 | 0.020 |
Why?
|
Aortography | 1 | 2009 | 419 | 0.020 |
Why?
|
Case Management | 1 | 2009 | 273 | 0.020 |
Why?
|
Femur | 1 | 2013 | 1302 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2005 | 7400 | 0.020 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2007 | 173 | 0.020 |
Why?
|
Intermittent Claudication | 1 | 2009 | 305 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2013 | 1259 | 0.020 |
Why?
|
Advisory Committees | 1 | 2010 | 789 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1266 | 0.020 |
Why?
|
Chlamydophila pneumoniae | 1 | 2005 | 52 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1918 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14656 | 0.020 |
Why?
|
Massachusetts | 1 | 1998 | 8805 | 0.020 |
Why?
|
Algorithms | 2 | 2020 | 13967 | 0.010 |
Why?
|
Data Interpretation, Statistical | 2 | 2005 | 2696 | 0.010 |
Why?
|
Emergency Treatment | 1 | 2008 | 498 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2010 | 2932 | 0.010 |
Why?
|
Life Tables | 1 | 2004 | 365 | 0.010 |
Why?
|
Partial Thromboplastin Time | 1 | 2004 | 206 | 0.010 |
Why?
|
Fractals | 1 | 2003 | 128 | 0.010 |
Why?
|
Publication Bias | 1 | 2003 | 162 | 0.010 |
Why?
|
Magnetic Resonance Angiography | 1 | 2009 | 1430 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2013 | 2129 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6771 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15766 | 0.010 |
Why?
|
Retreatment | 1 | 2001 | 600 | 0.010 |
Why?
|
Cineangiography | 1 | 1999 | 113 | 0.010 |
Why?
|
Patient Compliance | 1 | 2010 | 2689 | 0.010 |
Why?
|
Hemodynamics | 2 | 1999 | 4169 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2006 | 1342 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36030 | 0.010 |
Why?
|
Angiography | 1 | 2004 | 1605 | 0.010 |
Why?
|
Anthropometry | 1 | 2003 | 1348 | 0.010 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2000 | 296 | 0.010 |
Why?
|
Steroids | 1 | 2003 | 928 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 2003 | 785 | 0.010 |
Why?
|
Models, Cardiovascular | 1 | 2003 | 974 | 0.010 |
Why?
|
Apoptosis | 1 | 2014 | 9497 | 0.010 |
Why?
|
P-Selectin | 1 | 2000 | 600 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 2633 | 0.010 |
Why?
|
Brain | 1 | 2023 | 26912 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2004 | 1784 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2009 | 4168 | 0.010 |
Why?
|
Emergencies | 1 | 2001 | 1217 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 3520 | 0.010 |
Why?
|
Heart | 1 | 2007 | 4392 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2003 | 2869 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9336 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2003 | 2218 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2002 | 5201 | 0.010 |
Why?
|
Chronic Disease | 1 | 2006 | 9283 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1999 | 3531 | 0.010 |
Why?
|
Sulfonamides | 1 | 1999 | 1973 | 0.010 |
Why?
|
Contrast Media | 1 | 1999 | 5301 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 1999 | 18134 | 0.000 |
Why?
|